INSR and cancer: The lack of mutations found in IGF proteins in cancer may hint that INSR/IGF1R signalling is not a key driver in many tumours, and together with cross talk between pathways, this could explain the lack of efficacy seen in clinical trials using several different types of IGF1R‐targeted agent.